Seattle, WA-based Talus Bioscience, Gene regulator profiling in live cells for drug development Raises $11.2 Million in New Funding led by Two Bear Capital, with participation from WRF Capital, NFX, YC Continuity Fund, Funders Club VC, and BoxOne Ventures.
Read also – [Funding News] Learning.com Secures Growth Funding from CIBC Innovation Banking
The additional funding from Talus Bio will also be used to develop the biotech company’s medicines discovery platform, known as Multiplexed Assays for the Rational Modulation of Transcription Factors (MARMOT). An Aug. 20 announcement states that the technique uses artificial intelligence (AI), computational biology, synthetic chemistry, and next-generation proteomics to quickly identify possible medication candidates.
Read also – [Funding News] Mindset Care Raises $13 Million in Funding
As a company, Talus Bioscience focuses on two parallel efforts to prove that our technology can open up the world of gene regulation for drug discovery: Developing internal programs against previously undruggable gene regulators in cancers with poor standard of care, and Partnering with pharma, biotech, and academic labs to help progress their pipeline of gene regulator
“With our growing team of leading data scientists, we can use tens of millions of data points generated from the MARMOT platform to predict the best places to look for new molecules to block disease-causing transcription factors,” Talus CEO and co-founder Alex Federation, Ph.D., said in the company release. “We’re just getting started as we source new partners to help advance the dozens of promising transcription factor candidates we have discovered to date.”
Talus Bioscience highly interdisciplinary team are pioneers in proteomics-first drug discovery for transcription factors, with more than 6,800 citations, 50% PhD scientists, and two “40-under-40” proteomicists. It’s team members cover a wide spectrum of scientific expertise and experience with backgrounds in medicinal chemistry, molecular biology, cancer research, mass spectrometry, computational science, and machine learning.
About Talus Bioscience
Talus Bioscience is a venture-backed early-stage biotechnology startup company working on drug development for gene regulators. Talus Bio spun out of two leading institutions in September 2020 (University of Washington and Altius Institute for Biomedical Sciences) and is located in Seattle, WA. We are building a data-enabled drug development platform that will focus primarily on small-molecule drug development in oncology.
Talus Bio’s platform measures a drug’s ability to disrupt a gene regulator within its natural, non-engineered cellular environment. Furthermore, a single experiment using the platform measures activity for about 1,000 gene regulators simultaneously, providing information on in-cell drug activity and specificity in a single experiment. To accomplish this, we combine innovative cell processing with high-sensitivity quantitative proteomics and advanced downstream analytics.
